Today's Rundown Featured Story | | | Friday, July 6, 2018 A phase 2 Alzheimer’s trial—once nearly consigned to the heap of disappointing attempts against the disease—has re-emerged with new positive results, showing that an anti-amyloid beta protofibril antibody can slow clinical symptom decline, as well as reduce the accumulation of plaque in the brain. |
|
|
Top Stories Friday, July 6, 2018 Dynacure has raised €47 million ($55 million) to take an antisense oligonucleotide therapy into the clinic. The French biotech picked up the centronuclear myopathy prospect from its cofounder, Ionis Pharmaceuticals. Friday, July 6, 2018 Cleara Biotech has raised seed funding to advance a program that reversed aspects of aging in mice. The modified FOXO4-p53 interfering peptide program made headlines last year when it restored the physical fitness, hair growth and kidney function of mice. Friday, July 6, 2018 Finnish drugmaker Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial. Friday, July 6, 2018 Ablynx’s chief medical officer, Robert Zeldin, has made the jump to Acceleron Pharma to serve as its new CMO, as the company looks to advance development of its lead hematologic drug candidate, luspatercept. Thursday, July 5, 2018 Harnessing the power of the body’s immune system has already proven to be effective in treating cancer. Scientists at Lehigh University are now borrowing that idea to power up existing antibiotics’ ability to attack drug-resistant bacteria. Thursday, July 5, 2018 In this week's EuroBiotech Report, AbbVie dumps its Galapagos combination, Novartis tears up its Aveo pact, Nextbiotix raises €7 million and more. Friday, July 6, 2018 Sanofi launches a global R&D hub in Chengdu, China, with a focus on clinical trial data; Takeda is looking to sell its legacy Osaka headquarters to help fund the Shire buyout; China's antibody player I-Mab nabs a massive $220 million funding round and more. Friday, July 6, 2018 Ex-Millennium chief Deborah Dunsire is named CEO of Lundbeck; Ablynx's CMO will take a post at Acceleron; PredictImmune appoints a new CEO and Novocure promotes its chief commercial officer. Those moves plus more hirings, firings and retirings throughout the industry. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. |
|
